VRNA (veronapharma.com) Market Value to Book Value Ratio

Official company branding of Verona Pharma PLC (VRNA)

The future of Verona Pharma plc (VRNA) is based on the successful market launch of its sole approved respiratory agent. This chart of the market capitalization to net asset ratio visualizes the market premium, where the 32.84 indicator expresses the state of the metric. Business development relies on strategic alliances with global networks, while a neutral geopolitical backdrop in the US and Europe minimizes external risks.

VRNA Verona Pharma Inc.: Market Value to Book Value in the range 07/04/2022 - 10/18/2025

Financial and market metric breakdowns for Verona Pharma PLC (VRNA)

- price and consensus price forecast:
Stock Price Verona Pharma plc|VRNA - Analyst Consensus Forecast
- market capitalization data:
Market Value Verona Pharma Corp|VRNA - Full Business Value
- book capitalization data:
Book Value per Share Verona Pharma|VRNA - Accounting Value of Company|Market Capitalization to Book Value Ratio veronapharma.com|VRNA - Company Total Assets
- debt and liquidity data:
Debt to Equity Verona Pharma plc|VRNA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Verona Pharma Corp|VRNA - Company Total Debt|Debts to Book Capitalization Verona Pharma Corp|VRNA - Company Long-Term Debts|Company Current Liabilities Verona Pharma
Initial company analysis:Verona Pharma plc - VRNA
Original product of Verona Pharma Corp

To assess the issuer's financial stability, the ratio of market capitalization to net asset value is used, which demonstrates the market premium over the business's book value. By analyzing the change in the ratio of market value to equity, an investor can see how expectations for Verona Pharma (VRNA) innovative drugs for the treatment of respiratory pathologies impact the company's valuation relative to its actual tangible assets.

Main competitors

HLN: Market Capitalization to Book Value Ratio|KVUE (kenvue.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Jyong Biotech MENS|Market Capitalization to Net Assets Ligand Pharmaceuticals Incorporated|Amneal Pharmaceuticals Inc (AMRX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Perrigo Corp (PRGO)|Market Capitalization to Book Value Ratio ALVO (Alvotech)|liquidia.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Galapagos (GLPG)|ANIP: Market Value to Book Value|MNKD (MannKind Corp.) - Market Value to Book Value Ratio|Amphastar Corp (AMPH) - Market Cap to Net Assets Ratio|PCRX (Pacira BioSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Market Cap to Net Assets Ratio|Market Value to Book Value AQST (Aquestive Therapeutics Inc)|SCPH: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value ipatherapeutics.com HYFT|Market Cap to Net Assets Ratio ABVC BioPharma, Inc. ABVC|Market Value to Book Value Ratio Cumberland Pharmaceuticals Inc CPIX|QNTM (Quantum BioPharma Limited) - Market Capitalization to Book Value Ratio|FGEN: Market-to-Book Ratio|Market Value to Book Value Ratio Telomir Pharmaceuticals TELO|RANI (Rani Therapeutics Holdings, Inc.) - Market Value to Book Value|Market Value to Book Value Ratio SNYR (Synergy CHC Corp.)|Market-to-Book Ratio RLYB|Market Value to Book Value Ratio Lexaria Bioscience LEXX|Capitalization to Book Value Ratio Pulmatrix Corporation (PULM)|Market Capitalization to Book Value Ratio PTHL (Pheton Holdings)|APM - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Lyra Therapeutics (LYRA)|IBO: Market Value to Book Value|Market Value to Book Value Ratio tnfpharma.com (TNFA)|cbdMD (YCBD) - Market Capitalization to Net Assets|PRFX - Market Capitalization to Book Value Ratio|Market Value to Book Value Auris Medical|Market Capitalization to Book Value Ratio LIPO|Market Capitalization to Book Value Ratio OPTN (OptiNose Inc)|Market Value to Book Value Ratio Pieris|Procaps Group Corp - Market Value to Book Value|PTPI: Market Value to Book Value Ratio|QLI - Market Cap to Net Assets Ratio|SLRN: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio TFF Pharmaceuticals Inc.